VIENNA (EGMN) - Both diabetes itself and insulin therapy are associated with an increased risk for cancer, but the question of whether insulin glargine - or insulin analogues in general - are associated with a further increased risk remains open. Those were among the conclusions from five speakers at a special symposium, "Diabetes Therapy and Cancer," held during the annual meeting of the European Association for the Study of Diabetes. Although there has been a steady progression of research papers...